CANC Tema Oncology ETF
ETF on NASDAQ (US) · Actively managed · Listing
Most notable sale · Nuvalent Inc
Nuvalent Inc sold out
Units went from 53,763 to 0 ($5.93M → $0). Was 3.4% of the May 31, 2026 portfolio.
Most notable buy · Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. raised by 94%
Shares went from 32,598 to 63,165 ($2.17M → $6.73M). Now 3.2% of the portfolio. Estimated trade $3.26M.
Largest holding: Revolution Medicines, Inc., cut 29%, 61,768 shares ($12.7M).
| Current positions Top 10 | % of book |
|---|---|
| Revolution Medicines, Inc. RVMD $12.7M · −29% sh | 6.0% |
| Eli Lilly and Company LLY $10.9M · +22% sh | 5.2% |
| Cogent Biosciences, Inc. COGT $9.92M · +37% sh | 4.7% |
| Roche Holding AG RHHBY $8.81M · +16% units | 4.2% |
| Novartis AG NOVN $8.00M · +12% units | 3.8% |
| Bristol-Myers Squibb Company BMY $7.54M · +11% sh | 3.6% |
| Merck & Company, Inc. MRK $7.52M · −4% sh | 3.6% |
| AbbVie Inc. ABBV $7.01M · +20% sh | 3.3% |
| Halozyme Therapeutics, Inc. HALO $6.73M · +94% sh | 3.2% |
| Beone Medicines Ltd. ONC $6.71M · +62% sh | 3.2% |
Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against May 31, 2026.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 91.7% |
| Unclassified | 8.3% |
| Industries | % of holdings value |
|---|---|
| Biotechnology | 69.4% |
| Drug Manufacturers - General | 20.7% |
| Diagnostics & Research | 1.6% |
| Unclassified | 8.3% |
| Initiations 7 | Value |
|---|---|
| Kura Oncology, Inc. KURA 1.0% of portfolio | $2.17M |
| Tango Therapeutics, Inc. TNGX 0.9% of portfolio | $1.87M |
| Replimune Group, Inc. REPL 0.8% of portfolio | $1.66M |
| Candel Therapeutics, Inc. CADL 0.5% of portfolio | $1.13M |
| Bicara Therapeutics Inc. BCAX 0.4% of portfolio | $867K |
| Moderna, Inc. MRNA 0.3% of portfolio | $736K |
| Autolus Therapeutics plc AUTL 0.3% of portfolio | $630K |
| Increases 37 | Change |
|---|---|
| Halozyme Therapeutics, Inc. HALO $2.17M → $6.73M | +94% |
| Cogent Biosciences, Inc. COGT $7.22M → $9.92M | +37% |
| Beone Medicines Ltd. ONC $3.31M → $6.71M | +62% |
| Eli Lilly and Company LLY $8.49M → $10.9M | +22% |
| Tyra Biosciences, Inc. TYRA $527K → $2.14M | 5.4x |
| Johnson & Johnson JNJ $4.48M → $6.53M | +23% |
| Roche Holding AG RHHBY $7.42M → $8.81M | +16% |
| AbbVie Inc. ABBV $4.94M → $7.01M | +20% |
| Erasca, Inc. ERAS $1.90M → $3.72M | +41% |
| Iovance Biotherapeutics, Inc. IOVA $1.15M → $3.30M | +44% |
| Enliven Therapeutics, Inc. ELVN $2.30M → $4.31M | +28% |
| Novartis AG NOVN $7.10M → $8.00M | +12% |
| Reductions 14 | Change |
|---|---|
| Revolution Medicines, Inc. RVMD $13.6M → $12.7M | −29% |
| Immunome, Inc. IMNM $6.89M → $6.33M | −27% |
| AstraZeneca AZN $6.23M → $4.21M | −22% |
| ZAI Lab Limited ZLAB $3.48M → $4.11M | −18% |
| BridgeBio Pharma, Inc. BBIO $4.85M → $4.92M | −12% |
| ArriVent BioPharma, Inc. AVBP $1.29M → $653K | −49% |
| Celcuity Inc. CELC $6.31M → $3.82M | −10% |
| Amgen Inc. AMGN $3.71M → $4.34M | −8% |
| Inhibrx Biosciences, Inc. INBX $1.06M → $898K | −30% |
| Guardant Health, Inc. GH $1.42M → $1.40M | −20% |
| Syndax Pharmaceuticals, Inc. SNDX $1.41M → $1.06M | −24% |
| Merck & Company, Inc. MRK $6.29M → $7.52M | −4% |
| Terminations 5 | Change |
|---|---|
| Nuvalent Inc NUVL was $5.93M | −100% |
| Regeneron Pharmaceuticals, Inc. REGN was $1.31M | −100% |
| Chugai Pharmaceutical Co., Ltd. 4519 was $1.17M | −100% |
| Hutchmed (China) Limited HCM was $777K | −100% |
| SELLAS Life Sciences Group, Inc. SLS was $379K | −100% |
The other 25 increases
Genmab (+15%), Bristol-Myers Squibb Company (+11%), CG Oncology, Inc. (+13%), Natera, Inc. (+44%), Oric Pharmaceuticals, Inc. (+71%), Immunocore Holdings plc (+46%), Corvus Pharmaceuticals, Inc. (+32%), Relay Therapeutics, Inc. (+15%), Summit Therapeutics Inc. (+24%), IDEAYA Biosciences, Inc. (+5%), Exelixis, Inc. (+5%), Zymeworks Inc. (+5%), Nuvation Bio Inc. (+5%), UroGen Pharma Ltd. (+5%), Arcus Biosciences, Inc. (+5%), AnaptysBio, Inc. (+5%), Legend Biotech Corporation (+2%), Immatics N.V. (+5%), Cullinan Therapeutics, Inc. (+5%), Janux Therapeutics, Inc. (+5%) and 5 more
The other 2 reductions
First Tracks Biotherapeutics, Inc. (−1%), Gilead Sciences, Inc. (−<1%)
Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Aug 31, 2026 (Form N-PORT) vs the portfolio of May 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Jul 2, 2026.
Tema Oncology ETF (the "Fund") seeks to provide long-term growth.
Principal investment strategies
Under normal circumstances, the Fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The Tema ETF LLC (the "Adviser"), the Fund's investment adviser, will use internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms, diagnostic focused businesses with products used to diagnose cancer (such as liquid biopsies or cancer genomic screening), medical device companies focused on cancer treatment, and healthcare service providers with a specific strategic focus on helping treat and manage cancer. 1 The Fund generally is expected to consist of more than 15 companies but not more than 100 companies. The number of constituents may change depending on the number of companies available for investment that meet the Fund's criteria. To be eligible for inclusion in the Fund, a company must have a market capitalization of at least $100 million and there is no upper limit on the market capitalization of a portfolio company. To be eligible for inclusion in the Fund, a company must have a three-month average daily traded value of at least $500,000. A significant portion of the Fund's assets are expected to be invested in the United States and Europe. The Fund will not engage in currency hedging and is expected to own foreign currency for short periods of time for the purposes of buying and selling non-US listed securities and collecting dividends and/or coupon payments from those securities. The Fund is classified as a "non-diversified" investment company under the Investment Company Act of 1940, as amended (the "1940 Act"), which means that it may invest a high percentage of its assets in a limited number of issuers. The basic investment philosophy of the Adviser is to seek to invest in companies within the aforementioned thematic universe that are attractively valued when compared to their fundamentals and growth opportunities. The Adviser's security selection process for identifying companies within the aforementioned theme uses both "top down" idea generation (sector, theme, company research) and "bottom up" security selection (valuation, fundamental, quantitative, qualitative measures) approaches. In practice "top down" idea generation means fundamental sector research, quantitative tools (for example screening based on metrics such as five-year historic revenue growth, margins, or returns on invested capital) and the Adviser's own expertise, are used to narrow down the specific thematic research universe. Once this is defined "bottom up" security analysis involves the Adviser comparing valuation multiples (such as free cash flow yield, price to book ratio and price to earnings ratio or enterprise value to total invested capital, among others) to fundamental metrics (such as organic revenue growth, margins, returns on invested capital and equity, among others). Investments are deemed attractively valued when compared to fundamentals if the valuation multiples are below and fundamentals are above either (1) peers (2) the companies own historic averages (3) or prospective forecasts (as determined by the Adviser). Buttressing this is a detailed fundamental research profile of each company assessing business model, competitive edge, management incentives and track record, and balance sheet. The Adviser integrates environmental, social and corporate governance ("ESG") considerations into its investment analysis. This is in support of both the objective of maximizing return and the broader analysis of risks associated with individual companies.
Management and Contact
- Adviser
- Tema ETFs LLC
- Sub-adviser
- Tidal Investments LLC
- Portfolio managers
-
Maurits Pot, Yuri Khodjamirian, and David Song (all since inception, August 2023).
Sub-Adviser – Tidal Investments LLC.
Portfolio Managers – Qiao Duan and Andy Hicks (since February 2026).
- Phone
- 1.888.744.1377
- Website
- temaetfs.com
Track Record as of Feb 28, 2026
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | Since Inception | |
|---|---|---|
| Return Before Taxes | 42.78% | 16.09% |
| Return After Taxes on Distributions | 42.76% | 15.44% |
| Return After Taxes on Distributions and Sale of Fund Shares | 25.34% | 12.21% |
| S&P 500 Total Return Index | 17.88% | 21.05% |
Holdings as of Aug 31, 2026
The full portfolio as of the quarter end Aug 31, 2026, from the fund's report to the SEC (Form N-PORT, filed Oct 30, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of May 31, 2026.
59 lines, 56 linked, weights sum to 100.05% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| Revolution Medicines Inc | RVMD US76155X1000 | Equity | 61,768 | −24,682 | 6.02% | $ 12.698M |
| Eli Lilly & Co | LLY US5324571083 | Equity | 9,404 | +1,720 | 5.15% | $ 10.878M |
| Cogent Biosciences Inc | COGT US19240Q2012 | Equity | 283,440 | +77,021 | 4.70% | $ 9.92M |
|
Roche Holding AG
|
RHHBY US7711951043 | Equity | 164,068 | +22,415 | 4.17% | $ 8.81M |
|
Novartis AG
|
NOVN CH0012005267 | Equity | 52,465 | +5,445 | 3.79% | $ 8M |
| Bristol-Myers Squibb Co | BMY US1101221083 | Equity | 112,924 | +11,244 | 3.57% | $ 7.544M |
| Merck & Co Inc | MRK US58933Y1055 | Equity | 50,878 | −2,100 | 3.56% | $ 7.518M |
| AbbVie Inc | ABBV US00287Y1091 | Equity | 27,338 | +4,638 | 3.32% | $ 7.01M |
| Halozyme Therapeutics Inc | HALO US40637H1095 | Equity | 63,165 | +30,567 | 3.19% | $ 6.726M |
| BeOne Medicines Ltd | ONC US07725L1026 | Equity | 18,669 | +7,164 | 3.18% | $ 6.713M |
| Johnson & Johnson | JNJ US4781601046 | Equity | 24,555 | +4,655 | 3.09% | $ 6.528M |
| Immunome Inc | IMNM US45257U1088 | Equity | 230,958 | −84,690 | 3.00% | $ 6.331M |
| Genmab A/S | GMAB US3723032062 | Equity | 183,357 | +24,496 | 2.88% | $ 6.08M |
| CG oncology Inc | CGON US1569441009 | Equity | 77,547 | +8,845 | 2.76% | $ 5.828M |
| Ideaya Biosciences Inc | IDYA US45166A1025 | Equity | 142,271 | +6,424 | 2.70% | $ 5.705M |
| Exelixis Inc | EXEL US30161Q1040 | Equity | 101,461 | +4,576 | 2.63% | $ 5.544M |
| Bridgebio Pharma Inc | BBIO US10806X1028 | Equity | 64,261 | −8,930 | 2.33% | $ 4.922M |
| Amgen Inc | AMGN US0311621009 | Equity | 10,097 | −922 | 2.06% | $ 4.34M |
| Enliven Therapeutics Inc | ELVN US29337E1029 | Equity | 74,478 | +16,281 | 2.04% | $ 4.312M |
| AstraZeneca PLC | AZN GB0009895292 | Equity | 25,983 | −7,518 | 2.00% | $ 4.214M |
| Legend Biotech Corp | LEGN US52490G1022 | Equity | 197,934 | +3,842 | 1.95% | $ 4.113M |
| Zai Lab Ltd | ZLAB US98887Q1040 | Equity | 161,278 | −35,694 | 1.95% | $ 4.106M |
| Celcuity Inc | CELC US15102K1007 | Equity | 42,837 | −4,613 | 1.81% | $ 3.815M |
| Erasca Inc | ERAS US29479A1088 | Equity | 208,197 | +60,369 | 1.76% | $ 3.723M |
| Relay Therapeutics Inc | RLAY US75943R1023 | Equity | 185,142 | +24,066 | 1.61% | $ 3.403M |
| Iovance Biotherapeutics Inc | IOVA US4622601007 | Equity | 403,718 | +123,670 | 1.56% | $ 3.298M |
| Zymeworks Inc | ZYME US98985Y1082 | Equity | 110,609 | +4,994 | 1.54% | $ 3.253M |
| Nuvation Bio Inc | NUVB US67080N1019 | Equity | 416,638 | +21,325 | 1.31% | $ 2.775M |
| UroGen Pharma Ltd | URGN IL0011407140 | Equity | 61,279 | +2,761 | 1.25% | $ 2.641M |
| Arcus Biosciences Inc | RCUS US03969F1093 | Equity | 87,067 | +3,927 | 1.21% | $ 2.549M |
| Kura Oncology Inc | KURA US50127T1097 | Equity | 171,385 | new +171,385 | 1.03% | $ 2.168M |
| Gilead Sciences Inc | GILD US3755581036 | Equity | 14,646 | −46 | 1.02% | $ 2.143M |
| Tyra Biosciences Inc | TYRA US90240B1061 | Equity | 85,323 | +69,543 | 1.01% | $ 2.136M |
| Summit Therapeutics Inc | SMMT US86627T1088 | Equity | 150,035 | +28,938 | 0.97% | $ 2.043M |
| Corvus Pharmaceuticals Inc | CRVS US2210151005 | Equity | 142,722 | +34,245 | 0.95% | $ 2.004M |
| Natera Inc | NTRA US6323071042 | Equity | 6,084 | +1,846 | 0.93% | $ 1.959M |
| Tango Therapeutics Inc | TNGX US87583X1090 | Equity | 81,952 | new +81,952 | 0.89% | $ 1.872M |
| AnaptysBio Inc | ANAB US0327241065 | Equity | 32,744 | +1,474 | 0.88% | $ 1.867M |
| Immatics NV | IMTX NL0015285941 | Equity | 179,617 | +8,118 | 0.81% | $ 1.712M |
| Replimune Group Inc | REPL US76029N1063 | Equity | 108,413 | new +108,413 | 0.79% | $ 1.659M |
| Immunocore Holdings PLC | IMCR US45258D1054 | Equity | 44,900 | +14,051 | 0.77% | $ 1.631M |
| Cullinan Therapeutics Inc | CGEM US2300311063 | Equity | 65,785 | +2,959 | 0.69% | $ 1.452M |
| Guardant Health Inc | GH US40131M1099 | Equity | 8,773 | −2,213 | 0.66% | $ 1.395M |
| ORIC Pharmaceuticals Inc | ORIC US68622P1093 | Equity | 99,043 | +41,066 | 0.61% | $ 1.287M |
| Candel Therapeutics Inc | CADL US1374041093 | Equity | 86,337 | new +86,337 | 0.53% | $ 1.128M |
| Syndax Pharmaceuticals Inc | SNDX US87164F1057 | Equity | 54,962 | −17,250 | 0.50% | $ 1.06M |
| Janux Therapeutics Inc | JANX US47103J1051 | Equity | 53,953 | +2,431 | 0.47% | $ 983.024K |
| Inhibrx Biosciences Inc | INBX US45720N1037 | Equity | 7,084 | −3,086 | 0.43% | $ 897.543K |
| Olema Pharmaceuticals Inc | OLMA US68062P1066 | Equity | 83,532 | +3,773 | 0.41% | $ 871.239K |
| Bicara Therapeutics Inc | BCAX US0554771032 | Equity | 37,499 | new +37,499 | 0.41% | $ 866.977K |
| BridgeBio Oncology Therapeutic | BBOT US1079241022 | Equity | 97,750 | +4,411 | 0.41% | $ 860.2K |
| CytomX Therapeutics Inc | CTMX US23284F1057 | Equity | 241,337 | +12,350 | 0.38% | $ 810.892K |
| Arvinas Inc | ARVN US04335A1051 | Equity | 88,095 | +3,971 | 0.38% | $ 810.474K |
|
First American Treasury Obliga
|
FXFXX US31846V3289 | Money market | 807,908.68 | −1,112,400.27 | 0.38% | $ 807.909K |
| First Tracks Biotherapeutics I | TRAX US3371851029 | Equity | 19,205 | −39,214 | 0.38% | $ 803.537K |
| Moderna Inc | MRNA US60770K1079 | Equity | 5,247 | new +5,247 | 0.35% | $ 736.364K |
| Adlai Nortye Group Ltd | ANL US00704R1095 | Equity | 46,444 | +2,090 | 0.31% | $ 659.04K |
| ArriVent Biopharma Inc | AVBP US04272N1028 | Equity | 21,729 | −21,015 | 0.31% | $ 652.956K |
| Autolus Therapeutics PLC | AUTL US05280R1005 | Equity | 268,127 | new +268,127 | 0.30% | $ 630.098K |
Trades May 31, 2026 to Aug 31, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
|
Nuvalent Inc
|
NUVL | Closed | 53,763 | — | −53,763 | $ -5.935M |
| Revolution Medicines Inc | RVMD | Sold | 86,450 | 61,768 | −24,682 | $ -5.074M |
| Halozyme Therapeutics Inc | HALO | Bought | 32,598 | 63,165 | +30,567 | $ 3.255M |
| Cogent Biosciences Inc | COGT | Bought | 206,419 | 283,440 | +77,021 | $ 2.696M |
| BeOne Medicines Ltd | ONC | Bought | 11,505 | 18,669 | +7,164 | $ 2.576M |
| Immunome Inc | IMNM | Sold | 315,648 | 230,958 | −84,690 | $ -2.321M |
| Kura Oncology Inc | KURA | New | — | 171,385 | +171,385 | $ 2.168M |
| Eli Lilly & Co | LLY | Bought | 7,684 | 9,404 | +1,720 | $ 1.99M |
| Tango Therapeutics Inc | TNGX | New | — | 81,952 | +81,952 | $ 1.872M |
| Tyra Biosciences Inc | TYRA | Bought | 15,780 | 85,323 | +69,543 | $ 1.741M |
| Replimune Group Inc | REPL | New | — | 108,413 | +108,413 | $ 1.659M |
| First Tracks Biotherapeutics I | TRAX | Sold | 58,419 | 19,205 | −39,214 | $ -1.641M |
| Regeneron Pharmaceuticals Inc | REGN | Closed | 2,138 | — | −2,138 | $ -1.314M |
| Johnson & Johnson | JNJ | Bought | 19,900 | 24,555 | +4,655 | $ 1.238M |
| AstraZeneca PLC | AZN | Sold | 33,501 | 25,983 | −7,518 | $ -1.219M |
|
Roche Holding AG
|
RHHBY | Bought | 141,653 | 164,068 | +22,415 | $ 1.204M |
| AbbVie Inc | ABBV | Bought | 22,700 | 27,338 | +4,638 | $ 1.189M |
| Chugai Pharmaceutical Co Ltd | 4519 | Closed | 23,697 | — | −23,697 | $ -1.174M |
| Candel Therapeutics Inc | CADL | New | — | 86,337 | +86,337 | $ 1.128M |
| Erasca Inc | ERAS | Bought | 147,828 | 208,197 | +60,369 | $ 1.079M |
| Iovance Biotherapeutics Inc | IOVA | Bought | 280,048 | 403,718 | +123,670 | $ 1.01M |
| Enliven Therapeutics Inc | ELVN | Bought | 58,197 | 74,478 | +16,281 | $ 942.507K |
| Zai Lab Ltd | ZLAB | Sold | 196,972 | 161,278 | −35,694 | $ -908.769K |
| Bicara Therapeutics Inc | BCAX | New | — | 37,499 | +37,499 | $ 866.977K |
|
Novartis AG
|
NOVN | Bought | 47,020 | 52,465 | +5,445 | $ 830.272K |
| Genmab A/S | GMAB | Bought | 158,861 | 183,357 | +24,496 | $ 812.287K |
| HUTCHMED China Ltd | HCM | Closed | 67,823 | — | −67,823 | $ -776.573K |
| Bristol-Myers Squibb Co | BMY | Bought | 101,680 | 112,924 | +11,244 | $ 751.212K |
| Moderna Inc | MRNA | New | — | 5,247 | +5,247 | $ 736.364K |
| Bridgebio Pharma Inc | BBIO | Sold | 73,191 | 64,261 | −8,930 | $ -683.949K |
| CG oncology Inc | CGON | Bought | 68,702 | 77,547 | +8,845 | $ 664.79K |
| ArriVent Biopharma Inc | AVBP | Sold | 42,744 | 21,729 | −21,015 | $ -631.501K |
| Autolus Therapeutics PLC | AUTL | New | — | 268,127 | +268,127 | $ 630.098K |
| Natera Inc | NTRA | Bought | 4,238 | 6,084 | +1,846 | $ 594.338K |
| ORIC Pharmaceuticals Inc | ORIC | Bought | 57,977 | 99,043 | +41,066 | $ 533.447K |
| Immunocore Holdings PLC | IMCR | Bought | 30,849 | 44,900 | +14,051 | $ 510.332K |
| Corvus Pharmaceuticals Inc | CRVS | Bought | 108,477 | 142,722 | +34,245 | $ 480.8K |
| Relay Therapeutics Inc | RLAY | Bought | 161,076 | 185,142 | +24,066 | $ 442.333K |
| Celcuity Inc | CELC | Sold | 47,450 | 42,837 | −4,613 | $ -410.834K |
| Amgen Inc | AMGN | Sold | 11,019 | 10,097 | −922 | $ -396.349K |
| Summit Therapeutics Inc | SMMT | Bought | 121,097 | 150,035 | +28,938 | $ 394.136K |
| Inhibrx Biosciences Inc | INBX | Sold | 10,170 | 7,084 | −3,086 | $ -390.996K |
| SELLAS Life Sciences Group Inc | SLS | Closed | 40,702 | — | −40,702 | $ -378.936K |
| Guardant Health Inc | GH | Sold | 10,986 | 8,773 | −2,213 | $ -351.911K |
| Syndax Pharmaceuticals Inc | SNDX | Sold | 72,212 | 54,962 | −17,250 | $ -332.753K |
| Merck & Co Inc | MRK | Sold | 52,978 | 50,878 | −2,100 | $ -310.296K |
| Ideaya Biosciences Inc | IDYA | Bought | 135,847 | 142,271 | +6,424 | $ 257.602K |
| Exelixis Inc | EXEL | Bought | 96,885 | 101,461 | +4,576 | $ 250.033K |
| Zymeworks Inc | ZYME | Bought | 105,615 | 110,609 | +4,994 | $ 146.874K |
| Nuvation Bio Inc | NUVB | Bought | 395,313 | 416,638 | +21,325 | $ 142.025K |
| UroGen Pharma Ltd | URGN | Bought | 58,518 | 61,279 | +2,761 | $ 118.971K |
| Arcus Biosciences Inc | RCUS | Bought | 83,140 | 87,067 | +3,927 | $ 114.983K |
| AnaptysBio Inc | ANAB | Bought | 31,270 | 32,744 | +1,474 | $ 84.062K |
| Legend Biotech Corp | LEGN | Bought | 194,092 | 197,934 | +3,842 | $ 79.837K |
| Immatics NV | IMTX | Bought | 171,499 | 179,617 | +8,118 | $ 77.365K |
| Cullinan Therapeutics Inc | CGEM | Bought | 62,826 | 65,785 | +2,959 | $ 65.305K |
| Janux Therapeutics Inc | JANX | Bought | 51,522 | 53,953 | +2,431 | $ 44.293K |
| CytomX Therapeutics Inc | CTMX | Bought | 228,987 | 241,337 | +12,350 | $ 41.496K |
| Olema Pharmaceuticals Inc | OLMA | Bought | 79,759 | 83,532 | +3,773 | $ 39.352K |
| BridgeBio Oncology Therapeutic | BBOT | Bought | 93,339 | 97,750 | +4,411 | $ 38.817K |
| Arvinas Inc | ARVN | Bought | 84,124 | 88,095 | +3,971 | $ 36.533K |
| Adlai Nortye Group Ltd | ANL | Bought | 44,354 | 46,444 | +2,090 | $ 29.657K |
| Gilead Sciences Inc | GILD | Sold | 14,692 | 14,646 | −46 | $ -6,731.64 |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up